Trials / Completed
CompletedNCT05354050
Pharmacokinetic Study of DARE-BV1
A Phase 1 Single-center Pharmacokinetic Study of DARE-BV1 in Healthy Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Daré Bioscience, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DARE-BV1 | 2% Clindamycin 100 MG |
Timeline
- Start date
- 2020-11-03
- Primary completion
- 2020-11-18
- Completion
- 2020-12-02
- First posted
- 2022-04-29
- Last updated
- 2022-04-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05354050. Inclusion in this directory is not an endorsement.